Protara Therapeutics, Inc. Investment Income, Interest
Protara Therapeutics, Inc. (TARA) reported Investment Income, Interest of $1.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-11
- Protara Therapeutics, Inc. investment income, interest for the quarter ending 2026-06-30 was $1.66M, a 1.85% increase year-over-year.
- Protara Therapeutics, Inc. investment income, interest for the quarter ending 2026-03-31 was $1.85M, a 6.82% increase year-over-year.
- Protara Therapeutics, Inc. investment income, interest for the quarter ending 2025-12-31 was $1.52M, a 31.75% increase year-over-year.
- Protara Therapeutics, Inc. investment income, interest for the quarter ending 2025-09-30 was $1.50M, a 35.19% increase year-over-year.
- Protara Therapeutics, Inc. investment income, interest for fiscal 2025 was $6.38M, a 52.96% increase from fiscal 2024.
- Protara Therapeutics, Inc. investment income, interest for fiscal 2024 was $4.17M, a 30.63% increase from fiscal 2023.
- Protara Therapeutics, Inc. investment income, interest for fiscal 2023 was $3.19M, a 187.66% increase from fiscal 2022.
- Protara Therapeutics, Inc. investment income, interest for fiscal 2022 was $1.11M, a 368.35% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.66M 10-Q · filed 2026-08-11 | $3.50M 10-Q · filed 2026-08-11 | $5.03M derived: sum of 3 quarters · filed 2026-08-11 | $6.53M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.85M 10-Q · filed 2026-05-13 | $3.37M derived: sum of 2 quarters · filed 2026-05-13 | $4.87M derived: sum of 3 quarters · filed 2026-05-13 | $6.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $3.02M derived: sum of 2 quarters · filed 2026-03-10 | $4.65M derived: sum of 3 quarters · filed 2026-08-11 | $6.38M 10-K · filed 2026-03-10 |
| 2025-09-30 | $1.50M 10-Q · filed 2025-11-10 | $3.13M derived: sum of 2 quarters · filed 2026-08-11 | $4.86M 10-Q · filed 2025-11-10 | $6.01M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.63M 10-Q · filed 2026-08-11 | $3.35M 10-Q · filed 2026-08-11 | $4.51M derived: sum of 3 quarters · filed 2026-08-11 | $5.62M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.73M 10-Q · filed 2026-05-13 | $2.88M derived: sum of 2 quarters · filed 2026-05-13 | $4.00M derived: sum of 3 quarters · filed 2026-05-13 | $5.14M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $2.27M derived: sum of 2 quarters · filed 2026-03-10 | $3.42M derived: sum of 3 quarters · filed 2026-03-10 | $4.17M 10-K · filed 2026-03-10 |
| 2024-09-30 | $1.11M 10-Q · filed 2025-11-10 | $2.26M derived: sum of 2 quarters · filed 2025-11-10 | $3.02M 10-Q · filed 2025-11-10 | $3.83M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $1.15M 10-Q · filed 2025-08-11 | $1.90M 10-Q · filed 2025-08-11 | $2.72M derived: sum of 3 quarters · filed 2025-08-11 | $3.56M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $756.00K 10-Q · filed 2025-05-08 | $1.58M derived: sum of 2 quarters · filed 2025-05-08 | $2.42M derived: sum of 3 quarters · filed 2025-05-08 | $3.26M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $820.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $1.66M derived: sum of 2 quarters · filed 2025-03-05 | $2.51M derived: sum of 3 quarters · filed 2025-03-05 | $3.19M 10-K · filed 2025-03-05 |
| 2023-09-30 | $840.00K 10-Q · filed 2024-11-12 | $1.69M derived: sum of 2 quarters · filed 2024-11-12 | $2.37M 10-Q · filed 2024-11-12 | $2.92M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $846.00K 10-Q · filed 2024-08-06 | $1.53M 10-Q · filed 2024-08-06 | $2.08M derived: sum of 3 quarters · filed 2024-08-06 | $2.36M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $687.00K 10-Q · filed 2024-05-02 | $1.23M derived: sum of 2 quarters · filed 2024-05-02 | $1.51M derived: sum of 3 quarters · filed 2024-05-02 | $1.68M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $542.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $825.00K derived: sum of 2 quarters · filed 2024-03-13 | $991.00K derived: sum of 3 quarters · filed 2024-03-13 | $1.11M 10-K · filed 2024-03-13 |
| 2022-09-30 | $283.00K 10-Q · filed 2023-11-03 | $449.00K derived: sum of 2 quarters · filed 2023-11-03 | $568.00K 10-Q · filed 2023-11-03 | $627.00K derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $166.00K 10-Q · filed 2023-08-03 | $285.00K 10-Q · filed 2023-08-03 | $344.00K derived: sum of 3 quarters · filed 2023-08-03 | $397.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $119.00K 10-Q · filed 2023-05-04 | $178.00K derived: sum of 2 quarters · filed 2023-05-04 | $231.00K derived: sum of 3 quarters · filed 2023-05-04 | $241.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $112.00K derived: sum of 2 quarters · filed 2023-03-08 | $122.00K derived: sum of 3 quarters · filed 2023-03-08 | $237.00K 10-K · filed 2023-03-08 |
| 2021-09-30 | $53.00K 10-Q · filed 2022-11-03 | $63.00K derived: sum of 2 quarters · filed 2022-11-03 | $178.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $10.00K 10-Q · filed 2022-08-09 | $125.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $115.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $500.00K 10-K · filed 2022-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |